GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (STU:OJU1) » Definitions » Long-Term Capital Lease Obligation

Oramed Pharmaceuticals (STU:OJU1) Long-Term Capital Lease Obligation : €0.17 Mil (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Long-Term Capital Lease Obligation?

Oramed Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.17 Mil.

Oramed Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Mar. 2024 (€0.25 Mil) to Jun. 2024 (€0.22 Mil) and declined from Jun. 2024 (€0.22 Mil) to Sep. 2024 (€0.17 Mil).

Oramed Pharmaceuticals's annual Long-Term Capital Lease Obligation increased from Aug. 2021 (€0.34 Mil) to Dec. 2022 (€0.61 Mil) but then declined from Dec. 2022 (€0.61 Mil) to Dec. 2023 (€0.31 Mil).


Oramed Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Oramed Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Long-Term Capital Lease Obligation Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.34 0.61 0.31

Oramed Pharmaceuticals Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.31 0.25 0.22 0.17

Oramed Pharmaceuticals  (STU:OJU1) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Oramed Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Oramed Pharmaceuticals Headlines

No Headlines